Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation

Modern Pathology

Volumn 19, Issue 5, 2006, Pages 708-716

  Dumoff, Kimberly L ^a   Chu, Christina S ^a   Harris, Eleanor E ^a   Holtz, David ^b   Xu, Xiaowei ^a   Zhang, Paul J ^a   Acs, Geza ^a,c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b LANKENAU HOSPITAL   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cervix carcinoma; D2 40 antibody; Lymph node metastasis; Lymphatic invasion; Podoplanin; Prognostic marker

Indexed keywords

PODOPLANIN;

ADULT; ADVANCED CANCER; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE FREE INTERVAL; FEMALE; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA;

BIOPSY; CARCINOMA, SQUAMOUS CELL; CERVIX UTERI; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; UTERINE CERVICAL NEOPLASMS;

EID: 33646151164     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800580     Document Type: Article

References (33)

1. Sleeman JP. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent results. Cancer Res 2000;157:55-81.
2. Stacker SA, Achen MG, Jussila L, et al. Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2002;2:573-583.
3. Stacker SA, Baldwin ME, Achen MG. The role of tumor lymphangiogenesis in metastatic spread. FASEB J 2002;16:922-934.
4. Van Bommel PF, van Lindert AC, Kock HC, et al. A review of prognostic factors in early-stage carcinoma of the cervix (FIGO I B and II A) and implications for treatment strategy. Eur J Obstet Gynecol Reprod Biol 1987;26:69-84.
5. Hoskins WJ. Prognostic factors for risk of recurrence in stages Ib and IIa cervical cancer. Baillieres Clin Obstet Gynaecol 1988;2:817-828.
6. Robert ME, Fu YS. Squamous cell carcinoma of the uterine cervix - a review with emphasis on prognostic factors and unusual variants. Semin Diagn Pathol 1990;7:173-189.
7. Lai CH, Huang KG, Hong JH, et al. Randomized trial of surgical staging (extraperitoneal or laparoscopic) vs clinical staging in locally advanced cervical cancer. Gynecol Oncol 2003;89:160-167.
8. Piver MS, Barlow JJ, Krishnamsetty R. Five-year survival (with no evidence of disease) in patients with biopsy-confirmed aortic node metastasis from cervical carcinoma. Am J Obstet Gynecol 1981;139:575-578.
9. Twiggs LB, Potish RA. Decision theory analysis of the enteric morbidity and surgical staging in the treatment of advanced cervical cancer. Am J Obstet Gynecol 1984;148:134-140.
10. Haie C, Pejovic MH, Gerbaulet A, et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. Radiother Oncol 1988;11:101-112.
11. Rotman M, Pajak TF, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. JAMA 1995;274:387-393.
12. Marks A, Sutherland DR, Bailey D, et al. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumours. Br J Cancer 1999;80:569-578.
13. Schacht V, Dadras SS, Johnson LA, et al. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913-921.
14. Franchi A, Gallo O, Massi D, et al. Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer 2004;101:973-978.
15. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.
16. Dumoff KL, Chu C, Xu X, et al. Low D2-40 immunoreactivity correlates with lymphatic invasion and nodal metastasis in early-stage squamous cell carcinoma of the uterine cervix. Mod Pathol 2005;18:97-104.
17. Gombos Z, Xu X, Chu CS, et al. Peritumoral lymphatic vessel density and vascular endothelial growth factor-C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res 2005;11:8364-8371.
18. Pecorelli S, Benedet JL, Creasman WT, et al. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet 1999;65:243-249.
19. Kurman RJ, Norris HJ, Wilkinson EJ. Tumors of the Cervix, Vagina, and Vulva. Armed Forces Institute of Pathology: Washington, DC, 1992.
20. Hirakawa S, Hong YK, Harvey N, et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003;162:575-586.
21. Wetterwald A, Hoffstetter W, Cecchini MG, et al. Characterization and cloning of the E11 antigen, a marker expressed by rat osteoblasts and osteocytes. Bone 1996;18:125-132.
22. Breiteneder-Geleff S, Matsui K, Soleiman A, et al. Podoplanin, novel 43-kD membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol 1997;151:1141-1152.
23. Schacht V, Ramirez MI, Hong YK, et al. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003;22:3546-3556.
24. Martin-Villar E, Scholl FG, Gamallo C, et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005;113:899-910.
25. Kato Y, Kaneko M, Sata M, et al. Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005;26:195-200.
26. Sutherland DR, Rudd CE, Greaves MF. Isolation and characterization of a human T lymphocyte-associated glycoprotein (gp40). J Immunol 1984;133:327-333.
27. Carraway KL, Hull SR. O-glycosylation pathway for mucin-type glycoproteins. BioEssays 1989;10:117-121.
28. Lesuffleur T, Zweibaum A, Real FX. Mucins in normal and neoplastic human gastrointestinal tissues. Crit Rev Oncol Hematol 1994;17:153-180.
29. Klapper LN, Kirschbaum MH, Sela M, et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000;77:25-79.
30. Carraway KL, Perez A, Idris N, et al. Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol 2002;71:149-185.
31. Komatsu M, Jepson S, Arango ME, et al. Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor. Oncogene 2001;20:461-470.
32. Yamamoto M, Bharti A, Li Y, et al. Interaction of the DF3/MUC1 breast carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol Chem 1997;272:12492-12494.
33. Wesseling J, van der Valk SW, Vos HL, et al. Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 1995;129:255-265.